Medpace Holdings Inc
NASDAQ:MEDP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
284.87
457.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Medpace Holdings Inc
Medpace Holdings Inc
Net Issuance of Common Stock
Medpace Holdings Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medpace Holdings Inc
NASDAQ:MEDP
|
Net Issuance of Common Stock
$16.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Net Issuance of Common Stock
-$3B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Danaher Corp
NYSE:DHR
|
Net Issuance of Common Stock
-$5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Net Issuance of Common Stock
-$791.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-57%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Net Issuance of Common Stock
-$493m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-13%
|
|
Medpace Holdings Inc
Glance View
Medpace Holdings Inc., a name renowned in the clinical research sector, operates at the heart of the drug development process. Founded in 1992 by Dr. August Troendle, Medpace carved a niche for itself as a full-service clinical contract research organization (CRO). The essence of its operation lies in managing the complex journey of bringing new pharmaceuticals and medical devices from conception through to approval. Medpace partners with various biopharmaceutical companies to design, conduct, and oversee clinical trials, aligning with regulatory requirements to ensure these products are safe and effective. The company stands out by offering a comprehensive suite of services, including strategic consulting, project management, and the integration of cutting-edge technologies—a holistic approach that often distinguishes it from competitors. The engine driving Medpace’s profitability is its model of operational excellence fueled by its disciplined and integrated approach. The company generates revenue primarily from the contracts it secures with sponsors for conducting each phase of clinical trials. By closely collaborating with its clients, Medpace ensures tailored solutions that operate under specified timelines and budgets, enhancing client retention and attracting new business. What truly underlines Medpace’s financial success is its ability to deliver high-quality results, evidenced by robust data captured during trials and the attainment of key endpoints. This reputation for quality not only nurtures client trust but also consolidates Medpace's standing as a pivotal player in the CRO industry, securing a sustainable revenue stream and ongoing growth in a competitive landscape.
See Also
What is Medpace Holdings Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
16.2m
USD
Based on the financial report for Sep 30, 2024, Medpace Holdings Inc's Net Issuance of Common Stock amounts to 16.2m USD.
What is Medpace Holdings Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
20%
You don't have any saved screeners yet
